Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verus Pharmaceuticals Inc.

www.veruspharm.com

Latest From Verus Pharmaceuticals Inc.

Alexza Finds New U.S. Marketing Partner For Adasuve In Teva

A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.

BioPharmaceutical United States

Elevation raises $30M to advance nebulised LAMA for COPD

Elevation Pharmaceuticals, a San Diego, California-based company focused on respiratory therapies, has closed a $30 million series B fundraising round led by new investor Novo Ventures. The funding is expected to help the three-year-old start-up advance its nebulised long-acting muscarinic antagonist (LAMA), EP-101, for the treatment of chronic obstructive pulmonary disease (COPD), and complete Phase II testing.

Respiratory Cardiovascular

Deals Of The Week: Amgen/Watson, Baxter/Momenta, Takeda/Intellikine

Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.

BioPharmaceutical Europe

Meritage Pharma Inc.

Meritage Pharma was built by serial biotech entrepreneur Cam Garner around a viscous formulation of budesonide designed to coat the inflamed throat. It is now in Phase II trials for an orphan indication, pediatric eosinophilic esophagitis, an inflammation of the esophagus that appears to be triggered by allergies. Meritage's decision to reformulate a compound with a well-established safety record is, like the choice to pursue an orphan drug designation, a risk- and cost-reducing maneuver that has helped other biotech companies achieve success.
BioPharmaceutical
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Verus Pharmaceuticals Inc.
  • Senior Management
  • Robert W Keith, Pres. & CEO
    Richard G Vincent, VP, CFO
    Peter W Schineller, SVP, Sales & Mktg.
    Malcolm R Hill, PharmD, SVP, R&D
    Paul E Cayer, SVP, Corp. Dev.
  • Contact Info
  • Verus Pharmaceuticals Inc.
    Phone: (858) 436-1600
    12671 High Bluff Dr.
    Ste. 200
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register